Please use this identifier to cite or link to this item:
|Title:||225Ac-DOTA-Substance P as a potential radiopharmaceutical for targeted alpha therapy of glioblastoma multiforme|
|Authors:||MAJKOWSKA PILIP AGNIESZKA; RIUS MONTRAVETA MARIA; BRUCHERTSEIFER FRANK; APOSTOLIDIS CHRISTOS; WEIS MIRJAM; BONELLI MILTON; LAURENZA MARTA; MORGENSTERN ALFRED|
|Publisher:||European Commission - Joint Reserach Centre|
|Type:||Articles in periodicals and books|
|Abstract:||Gliomas, particularly WHO grade IV glioblastoma multiforme (GBM) are one of the most common and aggressive primary types of the cancer of the central nervous system and are composed of morphologically diverse population of cells in the tumour mass. Despite all current forms of treatment such as advanced surgery techniques, radiation therapy and chemotherapy, the life expectancy of patients diagnosed with GBM is 12 to 15 months displaying the worst median overall survival among all human neoplasms. Targeted alpha therapy has been shown to overcome chemo- and radioresistance in vitro and thus presents a promising new approach for therapy of GBM. The findings that high affinity Substance P receptor NK1 is high consistently expressed in primary malignant gliomas and in the intratumoral and peritumoral vasculature makes this receptor a very attractive target for glioma cancer therapy.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.